Contribute
España
Italia
대한민국
日本
Français

Benzinga

Research
My Stocks
Tools
Free Benzinga Pro Trial

Health Care

Deal Dispatch: Yum! Brands Sells Pizza Hut, Fox Corp. Buys Roku For $22 Billion, Salesforce Acquires Fin
Deal Dispatch: Yum! Brands Sells Pizza Hut, Fox Corp. Buys Roku For $22 Billion, Salesforce Acquires Fin
Relmada's Cancer Drug Candidate Sparks Fresh Bullish Call
Relmada's Cancer Drug Candidate Sparks Fresh Bullish Call
Immix Biopharma Analyst Bullish But Flags Safety, Adoption Questions
Immix Biopharma Analyst Bullish But Flags Safety, Adoption Questions
Relmada's Cancer Drug Candidate Sparks Fresh Bullish Call
Relmada's Cancer Drug Candidate Sparks Fresh Bullish Call
Immix Biopharma Analyst Bullish But Flags Safety, Adoption Questions
Immix Biopharma Analyst Bullish But Flags Safety, Adoption Questions
Why Is Legend Biotech Stock Falling Thursday?
Why Is Legend Biotech Stock Falling Thursday?
Novo Nordisk Data Breach: Hackers Claim To Have Stolen Drug Research, Trial Data And AI Models
Novo Nordisk Data Breach: Hackers Claim To Have Stolen Drug Research, Trial Data And AI Models

Health Care Recent News

Butterfly Network Climbs On Midjourney Hype Despite FDA, Reimbursement Questions
Butterfly Network Climbs On Midjourney Hype Despite FDA, Reimbursement Questions
Butterfly says Midjourney unveils its medical scanner plans, while analysts weigh growth potential, FDA hurdles and reimbursement risks.
FDA Expands Merck Pneumococcal Shot Label To Include At-Risk Children And Teens
FDA Expands Merck Pneumococcal Shot Label To Include At-Risk Children And Teens
FDA Expands Merck CAPVAXIVE Use To At-Risk Children And Adolescents Aged 2-17 Following Positive Phase 3 STRIDE-13 Data.
Biogen To Acquire RayThera For Up To $1 Billion, Expanding Immunology Pipeline
Biogen To Acquire RayThera For Up To $1 Billion, Expanding Immunology Pipeline
Biogen acquires RayThera in a deal worth up to $1 billion, adding early-stage immunology assets as it expands beyond Alzheimer's disease.
Joe Rogan Says Former Presidents Contacted Spotify Behind The Scenes To Push For His Show's Removal: 'They Spent A Lot Of Money'
Joe Rogan Says Former Presidents Contacted Spotify Behind The Scenes To Push For His Show's Removal: 'They Spent A Lot Of Money'
Joe Rogan alleged former presidents contacted Spotify during the COVID controversy, claiming a coordinated effort to remove his podcast.
Marjorie Taylor Greene Reveals She Went To Mexico For Stem Cell Therapy Because US Health Insurance Is 'Absurdly Expensive'
Marjorie Taylor Greene Reveals She Went To Mexico For Stem Cell Therapy Because US Health Insurance Is 'Absurdly Expensive'
Marjorie Taylor Greene cites soaring healthcare costs as Gallup data shows fewer Americans can afford medical care.
Park Ha Biological Technology (BYAH) Stock Surges Over 41% After Hours: Why Is It Moving?
Park Ha Biological Technology (BYAH) Stock Surges Over 41% After Hours: Why Is It Moving?
Park Ha Biological Technology Co. shares surged 41.66% in after-hours trading following a $2 million direct offering announcement.
Jazz Pharmaceuticals Gains Oncology Firepower Through AbCellera Collaboration
Jazz Pharmaceuticals Gains Oncology Firepower Through AbCellera Collaboration
Jazz Pharmaceuticals teams with AbCellera on cancer therapies as analysts maintain positive targets despite a recent Zepzelca trial setback.
Verastem Stock Jumps As Data Shows Strong Survival Trends In Pancreatic Cancer
Verastem Stock Jumps As Data Shows Strong Survival Trends In Pancreatic Cancer
Verastem updated RAMP 205 data showed 86% six-month survival in metastatic pancreatic cancer and continued tumor shrinkage.
Leidos Analyst Is No Longer Bullish With Rising Pressure Across Health Care Portfolio
Leidos Analyst Is No Longer Bullish With Rising Pressure Across Health Care Portfolio
Leidos Holdings faces challenges in health care sector, offsetting strong defense portfolio. Analyst downgrades rating, cuts PT.
FDA Signals uniQure Huntington Gene Therapy Data Could Back Accelerated Approval
FDA Signals uniQure Huntington Gene Therapy Data Could Back Accelerated Approval
uniQure stock surged after the FDA said three-year AMT-130 data could support accelerated approval for Huntington's disease treatment.
Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved